VAPO News and Press, Vapotherm Inc. From 05/04/22

Revenue of $21.6 Million In-Line with Preliminary Revenue of $20.5 Million to $21.5 Million Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced first quarter 2022 financial results. First Quarter 2022 Summary ...

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy ® products which are used to treat patients of all ag...

Gainers: MedAvail MDVL +61%. Lyra Therapeutics LYRA +27%. Medicenna Therapeutics (MDNA) +25%. Biofrontera BFRI +23%. IsoPlexis (ISO) +8%. Losers: BioCryst Pharmaceuticals BCRX -33%. Sunshine Biopharma SBFM -33%. Werewolf Therapeutics (HOWL) -15%. I...

A late-day surge allowed the major U.S. equity averages to finish Thursday's trading with mild gains, reversing losses seen earlier in the day. The higher finish ended a two-day slide that included consecutive days of more than 2% declines from the Nasdaq. The health care sector helped buoy t...

Gainers: Momentus (MNTS) +49%. Trevi Therapeutics (TRVI) +49%. Sunshine Biopharma (SBFM) +34%. Werewolf Therapeutics (HOWL) +30%. System1 (SST) +27%. AppTech Payments (APCX) +22%. MiNK Therapeutics (INKT) +21%. Ikena Oncology (IKNA) +19%. Sprinklr (CXM) +18%. PhaseBio Pharmaceuticals (PHAS) +...

Gainers: Trevi Therapeutics (TRVI) +36%. Sunshine Biopharma (SBFM) +31%. IMAC Holdings (IMAC) +28%. Werewolf Therapeutics (HOWL) +25%. Ikena Oncology (IKNA) +22%. Losers: Aptinyx (APTX) -47%. Vapotherm (VAPO) -29%. Rite Aid (RAD) -23%. Biophytis (BPTS) -13%. Science 37 Holdings (SNC...

Piper Sandler has downgraded Vapotherm (NYSE:VAPO) stock ratings from "Overweight" to "Underweight," while raising concerns over the company's near-term business visibility. In a research note, Piper Sandler analysts Jason Bednar and Joseph Downing cut their price target on the stock from $23...

Aptinyx (APTX) -52% after reports results from Phase 2b study of NYX-2925 in painful diabetic peripheral neuropathy. Vapotherm (VAPO) -22% after withdraws FY22 guidance; sees Q1 revs below consensus. Rite Aid (RAD) -18% as Deutsche Bank slashes price target to $1. Bio...

Vapotherm (NYSE:VAPO) shares slid ~21% Wednesday evening after the respiratory technology developer reported prelim revenue of $20.5M to $21.5M for Q122 (consensus: $25.79M). The company had reported $32.3M revenue in Q121. Vapotherm also withdrew its previously announced guidance f...

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today announced preliminary unaudited revenue for the quarter ended March 31, 2022. The Company also announced withdrawal of its full year 2022 revenue guidance (issued on January 12, 2022 and reite...